Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
Author:
Visco CarloORCID, Di Rocco Alice, Evangelista Andrea, Quaglia Francesca MariaORCID, Tisi Maria Chiara, Morello Lucia, Zilioli Vittorio Ruggero, Rusconi Chiara, Hohaus StefanORCID, Sciarra Roberta, Re Alessandro, Tecchio Cristina, Chiappella Annalisa, Marin-Niebla AnaORCID, McCulloch Rory, Gini Guido, Perrone Tommasina, Nassi Luca, Pennese Elsa, Stefani Piero Maria, Cox Maria Christina, Bozzoli Valentina, Fabbri Alberto, Polli Valentina, Ferrero Simone, Celis Maria Isabel Alvarez De, Sica Antonello, Petrucci Luca, Arcaini LucaORCID, Rule SimonORCID, Krampera MauroORCID, Vitolo Umberto, Balzarotti Monica
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference25 articles.
1. Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–iv71. 2. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37:471–80. 3. McKay P, Leach M, Jackson R, Cook G, Rule S.British Committee for Standards in Haematology Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol. 2012;159:405–26. 4. Dreyling M, Aurer I, Cortelazzo S, Hermine O, Hess G, Jerkeman M, et al. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leuk Lymphoma. 2017;27:1–15. 5. Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185:940–4.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|